ReviewTrends in parasitology2026
Polypharmacology in malaria treatment: single drugs, multiple mechanisms, greater impact.
Review in Trends in parasitology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Malaria remains a global health crisis, exacerbated by the rise of drug-resistant strains of Plasmodium species to clinically used drugs, as well as newly developed therapeutic agents. Historically, natural-product-derived drugs such as quinine and artemisinin have been the cornerstones of malaria treatment, distinguished by their ability to attack the parasite on multiple fronts simultaneously. This review explores the paradigm of single drugs with multiple targets, a polypharmacology strategy designed to achieve combination-therapylike efficacy within a single compound. We discuss how natural products leverage multitarget mechanisms of action, reducing the likelihood of resistance, and the opportunities and challenges in developing next-generation antimalarials. Understanding and harnessing polypharmacology in antimalarial drug design could prolong therapeutic durability and reinvigorate our arsenal against malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.